Rhythm Pharmaceuticals, Inc. (RYTM): Agree - it is good company Will take ti...

Home > Boards > US Listed > Biotechs > Rhythm Pharmaceuticals, Inc. (RYTM)

Followed By	75
Posts	12374
Boards Moderated	0
Alias Born	04/03/2014

Thursday, March 11, 2021 8:25:36 AM

Re: None

Agree - it is good company
Will take time to make money but proof of product is there.

The valuation is fair at this point - upside maybe 50-70% by end of the year based on how they price and are able show sale.

The payment cycle with insurance will be key as the product is very high priced -

Recent RYTM News

Rhythm Pharmaceuticals Announces New Employment Inducement Grants • GlobeNewswire Inc. • 08/08/2022 08:01:00 PM
Needham Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM) • TipRanks • 08/08/2022 10:45:09 AM
Quarterly Report (10-q) • Edgar (US Regulatory) • 08/03/2022 08:21:07 PM
Rhythm Pharmaceuticals (RYTM) Receives a Hold from Morgan Stanley • TipRanks • 08/03/2022 04:42:26 PM
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference • GlobeNewswire Inc. • 08/03/2022 12:00:00 PM
Wall Street Analysts Are Bullish on Top Healthcare Picks • TipRanks • 08/03/2022 10:45:28 AM
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update • GlobeNewswire Inc. • 08/02/2022 11:00:00 AM
Rhythm Pharmaceuticals (RYTM) Received its Third Buy in a Row • TipRanks • 08/01/2022 01:55:37 PM
Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 07/28/2022 08:32:38 PM
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 • GlobeNewswire Inc. • 07/28/2022 12:00:00 PM
Rhythm Pharmaceuticals (RYTM) Received its Third Buy in a Row • TipRanks • 07/25/2022 09:55:46 AM
Rhythm Pharmaceuticals Gets Positive CHMP Opinion for Imcivree • Dow Jones News • 07/22/2022 01:33:00 PM
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome • GlobeNewswire Inc. • 07/22/2022 12:39:33 PM
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France • GlobeNewswire Inc. • 07/20/2022 12:00:00 PM
NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency • GlobeNewswire Inc. • 07/18/2022 10:00:00 AM
Rhythm Pharmaceuticals (RYTM) Gets a Hold Rating from Morgan Stanley • TipRanks • 07/15/2022 04:47:25 PM
Ladenburg Thalmann & Co. Remains a Buy on Rhythm Pharmaceuticals (RYTM) • TipRanks • 07/13/2022 10:45:13 AM
Needham Thinks Rhythm Pharmaceuticals’ Stock is Going to Recover • TipRanks • 07/12/2022 02:35:27 PM
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity • GlobeNewswire Inc. • 07/12/2022 11:00:00 AM
Statement of Ownership (sc 13g) • Edgar (US Regulatory) • 07/08/2022 08:58:33 PM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants • GlobeNewswire Inc. • 07/08/2022 01:00:00 PM
Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency • GlobeNewswire Inc. • 06/22/2022 12:01:00 PM
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment • GlobeNewswire Inc. • 06/22/2022 12:00:00 PM
Rhythm Pharma Higher After FDA Approves Supplemental NDA • Dow Jones News • 06/17/2022 04:06:00 PM
Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million • GlobeNewswire Inc. • 06/16/2022 08:02:00 PM

More RYTM News

InvestorsHub NewsWire

Pro Music Rights, Inc., one of the world's largest music licensing companies, announces that it intends to Release its Financials by August 19, 2022 • NUVG • Aug 11, 2022 11:11 AM

AXTG Partner with Save Planet Earth to digitize and plant 100 million trees with NFTs • AXTG • Aug 11, 2022 10:15 AM

PURA Announces New Development Expanding Cannabis Market Opportunity • PURA • Aug 11, 2022 9:34 AM

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis • KTTA • Aug 11, 2022 8:35 AM

SinglePoint Acquires Frontline Power Solutions, a Multi-State Licensed Energy Services Company • SING • Aug 11, 2022 8:30 AM

Pacific Booker Minerals Inc. Announces AGM Results and Project Update • PBMLF • Aug 11, 2022 7:30 AM

GALILEO ANNOUNCES THE START OF REVENUE GENERATION AND ITS EXPANSION PLAN. • MDRM • Aug 10, 2022 3:23 PM

ResGreen Powers Up - Introduces Wireless Battery Charging for its Fleet of Mobile Robots • RGGI • Aug 10, 2022 10:53 AM

Kona Gold Beverage, Inc Signs New Distribution Partners in California, Illinois, and Nevada • KGKG • Aug 10, 2022 9:00 AM

Investing in Quantum Computing: What Every Investor Needs to Know • GOOGL • Aug 10, 2022 8:45 AM

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic • BMY • Aug 10, 2022 8:45 AM

Mill City Ventures III, Ltd. provides 2nd Quarter Fiscal 2022 Guidance Revenue Increased 83% year over year and 83% for 6-month period • MCVT • Aug 10, 2022 8:44 AM

Branded Legacy, Inc. Cancels Another 60 Million Common Shares • BLEG • Aug 10, 2022 8:30 AM

Defiance Discovers Blind Silver System At Lucita • DEF • Aug 9, 2022 10:31 AM

USMJ Announces New York Adult Use Cannabis License • PURA • Aug 9, 2022 10:21 AM

Start posting your company's news
Only $200 per official company press release!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y

Detailed Quote

Follow Board

Keyboard Shortcuts

Report TOS Violation